Ruxolitinib and Decitabine Intensified Conditioning Regimen for Patients With High Risk Hematological Malignancies Underwenting Allogeneic Stem Cell Transplantation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Busulfan (Primary) ; Carmustine (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Decitabine (Primary) ; Ruxolitinib (Primary)
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Therapeutic Use

01 Nov 2024 Results (n=37) assessing the efficacy of ruxolitinib and decitabine plus modified busulfan-cyclophosphamide (mBu/Cy) conditioning for reducing relapse in high-risk AML after allo-HSCT, published in the Annals of Hematology
15 Jun 2023 Results (n=37)presented at the 28th Congress of the European Haematology Association
12 Oct 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com